LA
KYMR icon

LBP AM’s Kymera Therapeutics KYMR Stock Holding History

LBP AM’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Sell
17,947
-941
-5% -$80.9K 0.02% 314
2026
Q1 		$1.57M Buy
18,888
+13,221
+233% +$1.05M 0.02% 296
2025
Q4 		$441K Buy
+5,667
New +$383K 0.01% 391

Other funds holding KYMR

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

LBP AM's KYMR Position: Q2 2026 in Review

LBP AM reduced its Kymera Therapeutics (KYMR) stake by 5% in Q2 2026, selling an estimated $80.9K and leaving 17,947 shares worth $2.06M. The position accounts for 0.02% of the portfolio, ranked #314.

LBP AM first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 31 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • LBP AM held 17,947 shares of Kymera Therapeutics worth $2.06M as of Q2 2026.
  • LBP AM sold 941 Kymera Therapeutics shares in Q2 2026, an estimated $80.9K.
  • Kymera Therapeutics made up 0.02% of LBP AM's portfolio in Q2 2026, its #314 holding.
  • LBP AM first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 31 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on LBP AM's 13F filing for Q2 2026, filed 24 Jul 2026.